HIV vaccines 1983-2003

Nature Medicine

Volumn 9, Issue 7, 2003, Pages 874-880

  McMichael, Andrew J ^a   Hanke, Tomas ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CELL STIMULATION; DRUG RESEARCH; ENVELOPE GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; INFECTION RISK; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T LYMPHOCYTE; VACCINATION;

AIDS VACCINES; ANTIBODIES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; DRUG DESIGN; HIV; HUMANS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0038638590     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0703-874     Document Type: Review

References (112)

1. Blankson, J.N., Persaud, D. & Siliciano, R.F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53, 557-593 (2002).
2. Kwong, P.D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
3. McMichael, A. T cell responses and viral escape. Cell 93, 673-676 (1998).
4. Walker, B.D. & Korber, B.T. Immune control of HIV: the obstacles of HLA and viral diversity. Nat. Immunol. 2, 473-475 (2001).
5. + T-cell responses containing replication of the primary virus. Nature 420, 434-439 (2002).
6. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
7. Stott, J. & Almond, N. Assessing animal models of AIDS. Nat. Med. 1, 295-297 (1995).
8. Lifson, J.D. et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584-2593 (2000).
9. + lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J. Virol. 75, 10187-10199 (2001).
10. Townsend, A. et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959-968 (1986).
11. Berman, P.W. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625 (1990).
12. Lubeck, M.D. et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3, 651-658 (1997).
13. Girard, M. et al. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus. Virology 232, 98-104 (1997).
14. Emini, E.A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
15. Fultz, P.N. Immunization and challenge of chimpanzees with HIV-1. AIDS Res. Hum. Retroviruses 8, 1517-1519 (1992).
16. Girard, M. et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69, 6239-6248 (1995).
17. Berman, P.W. et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J. Infect. Dis. 176, 384-397 (1997).
18. Moore, J.P. et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-109 (1995).
19. Scarlatti, G. et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3, 1259-1265 (1997).
20. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
21. Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144-4149 (2003).
22. Moore, J.P., Parren, P.W. & Burton, D.R. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J. Virol. 75, 5721-5729 (2001).
23. Gauduin, M.C. et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3, 1389-1393 (1997).
24. Mascola, J.R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210 (2000).
25. Ruprecht, R.M. et al. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus. Clin. Biol. 8, 350-358 (2001).
26. Hofmann-Lehmann, R. et al. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J. Med. Primatol. 30, 190-196 (2001).
27. Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705-711 (1998).
28. Reitter, J.N., Means, R.E. & Desrosiers, R.C. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4, 679-684 (1998).
29. Murphey-Corb, M. et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246, 1293-1297 (1989).
30. Putkonen, P. et al. A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge. J. Med. Primatol. 21, 108-112 (1992).
31. Stott, E.J. et al. Anti-cell antibody in macaques. Nature 353, 393 (1991).
32. Fouts, T. et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. USA 99, 11842-11847 (2002).
33. Poveda, E. et al. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 16, 1959-1961 (2002).
34. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75, 11983-11991 (2001).
35. + T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
36. + T cells. Nature 417, 95-98 (2002).
37. Rosenberg, E.S. et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523-526 (2000).
38. Sun, J.C. & Bevan, M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
39. Shedlock, D.J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339 (2003).
40. Zajac, A.J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
41. Phillips, R.E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453-459 (1991).
42. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3, 205-211 (1997).
43. Price, D.A. et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94, 1890-1895 (1997).
44. Goulder, P.J. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212-217 (1997).
45. Goulder, P.J. et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412, 334-338 (2001).
46. Evans, D.T. et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5, 1270-1276 (1999).
47. O'Connor, D., Friedrich, T., Hughes, A., Allen, T.M. & Watkins, D. Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection. Immunol. Rev. 183, 115-126 (2001).
48. O'Connor, D.H., Allen, T.M. & Watkins, D.I. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies. DNA Cell Biol. 21, 659-664 (2002).
49. Vogel, T.U. et al. Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence? J. Virol. 76, 11623-11636 (2002).
50. + T cells. Science 270, 1811-1815 (1995).
51. Fu, T.M., Friedman, A., Ulmer, J.B., Liu, M.A. & Donnelly, J.J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 71, 2715-2721 (1997).
52. Ulmer, J.B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (1993).
53. Oehen, S., Waldner, H., Kundig, T.M., Hengartner, H. & Zinkernagel, R.M. Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J. Exp. Med. 176, 1273-1281 (1992).
54. Hsu, S.C. et al. Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-γ. Int. Immunol. 10, 1441-1447 (1998).
55. Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
56. Belyakov, I.M. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7, 1320-1326 (2001).
57. Rose, N.F. et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 539-549 (2001).
58. Shiver, J.W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
59. Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
60. Barouch, D.H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from CTL. Nature (in the press).
61. Horton, H. et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76, 7187-7202 (2002).
62. Willerford, D.M. et al. Human immunodeficiency virus infection among high-risk seronegative prostitutes in Nairobi. J. Infect. Dis. 167, 1414-1417 (1993).
63. Kreiss, J.K. et al. AIDS virus infection in Nairobi prostitutes. Spread of the epidemic to East Africa. N. Engl. J. Med. 314, 414-418 (1986).
64. Rowland-Jones, S.L. et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102, 1758-1765 (1998).
65. + lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest. 107, 1303-1310 (2001).
66. + responses. J. Clin. Invest. 107, 341-349 (2001).
67. Addo, M.M. et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77, 2081-2092 (2003).
68. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402 (1998).
69. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110 (1994).
70. Koup, R.A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
71. Wilson, J.D. et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 14, 225-233 (2000).
72. Appay, V. et al. Dynamics of T cell responses in HIV infection. J. Immunol. 168, 3660-3666 (2002).
73. Hanke, T. et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73, 7524-7532 (1999).
74. Allen, T.M. et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164, 4968-4978 (2000).
75. Barouch, D.H. et al. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol. Lett. 79, 57-61 (2001).
76. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397-402 (1998).
77. Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445 (1998).
78. McConkey, J.S. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729-735 (2003).
79. Kent, S.J. et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72, 10180-8 (1998).
80. Pialoux, G. et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group and l'Agence Nationale de Recherche sur le SIDA. AIDS Res. Hum. Retroviruses 11, 373-381 (1995).
81. Egan, M.A. et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-IMN.env gene. J. Infect. Dis. 171, 1623-1627 (1995).
82. Mossman, S.P. et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 70, 1953-1960 (1996).
83. Caley, I.J. et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71, 3031-3038 (1997).
84. Xin, K.Q. et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 12, 1047-1061 (2001).
85. Aldovini, A. & Young, R.A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351, 479-482 (1991).
86. Hone, D.M. et al. Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine. Dev. Biol. Stand. 82, 159-162 (1994).
87. Fouts, T.R., Tuskan, R.G., Chada, S., Hone, D.M. & Lewis, G.K. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Vaccine 13, 1697-1705 (1995).
88. Gaschen, B. et al. Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360 (2002).
89. + T-cell approach feasible? Nat. Rev. Immunol. 2, 283-291 (2002).
90. Boyer, J.D. et al. HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response. Dev. Biol. Stand. 95, 147-153 (1998).
91. Burrows, S.R. et al. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J. Exp. Med. 182, 1703-1715 (1995).
92. Boyer, J.D. et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J. Infect. Dis. 181, 476-483 (2000).
93. Cao, H. et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers; results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Infect. Dis. 187, 887-895 (2003).
94. Wee, E.G., Patel, S., McMichael, A.J. & Hanke, T. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J. Gen. Virol. 83, 75-80 (2002).
95. + memory T cells. J. Exp. Med. 186, 859-865 (1997).
96. Mwau, M., McMichael, A.J. & Hanke, T. Design and validation of an ELISPOT assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retroviruses 18, 611-618 (2002).
97. Smith, J.G., Liu, X., Kaufhold, R.M., Clair, J. & Caulfield, M.J. Development and validation of a γ interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagn. Lab. Immunol. 8, 871-887 (2001).
98. Currier, J.R. et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260, 157-172 (2002).
99. Hanke, T., & McMichael, A.J. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 6, 951-955 (2000).
100. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5, 518-525 (1999).
101. Sprent, J. & Tough, D.F. T cell death and memory. Science 293, 245-248 (2001).
102. Tough, D.F., Sun, S., Zhang, X. & Sprent, J. Stimulation of memory T cells by cytokines. Vaccine 18, 1642-1648 (2000).
103. Panicali, D., Davis, S.W., Weinberg, R.L. & Paoletti, E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 80, 5364-5368 (1983).
104. Mackett, M., Yilma, T., Rose, J.K. & Moss, B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 227, 433-435 (1985).
105. Dalgleish, A.G. et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 763-767 (1984).
106. Alkhatib, G. et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996).
107. Sattentau, Q.J., Moore, J.P., Vignaux, F., Traincard, F. & Poignard, P. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67, 7383-7393 (1993).
108. Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996).
109. Scanlan, C.N. et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 76, 7306-7321 (2002).
110. Pantophlet, R. et al. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77, 642-658 (2003).
111. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
112. + lymphocytes. Science 283, 857-60 (1999).